Abstract
Postaglandins(PG) and low-density lipoproteins (LDL) both are playing a key role in atherogenesis. Their interaction at the local vascular level is of central relevance in plaque formation and progression. Details of these complex actions however, still need to be elucidated. Lipoproteins are influencing the PG-production of arterial wall cells and platelets, while PGs in turn have been shown to regulate lipoprotein receptor binding and entry into the arterial wall. Modification of LDL severely influences arterial wall trapping and foam cell formation. During LDL-modification, isoprostanes, a new family of compounds generated by free radical catalysed action, independent of cyclooxygenase, are formed. 8-epi PGF 2a the most well known member exerts a great variety of proatherogenic actions, among them vasoconstriction and platelet activation it also serves as a mitogen and stimulator of endothelin release. The influence of various eicosanoids on lipoprotein modification, however, has not been assessed yet.
Keywords: Lipid Modification, low density lipoproteins, PG production, LDL modification, proatherogenic actions, cholesteryl esters, Lipid Peroxidation, tocopheroxyl radical TO, endothelial integrity
Current Pharmaceutical Design
Title: Prostaglandins and Lipid Modification
Volume: 7 Issue: 6
Author(s): Grazyna Sobal and H. Sinzinger
Affiliation:
Keywords: Lipid Modification, low density lipoproteins, PG production, LDL modification, proatherogenic actions, cholesteryl esters, Lipid Peroxidation, tocopheroxyl radical TO, endothelial integrity
Abstract: Postaglandins(PG) and low-density lipoproteins (LDL) both are playing a key role in atherogenesis. Their interaction at the local vascular level is of central relevance in plaque formation and progression. Details of these complex actions however, still need to be elucidated. Lipoproteins are influencing the PG-production of arterial wall cells and platelets, while PGs in turn have been shown to regulate lipoprotein receptor binding and entry into the arterial wall. Modification of LDL severely influences arterial wall trapping and foam cell formation. During LDL-modification, isoprostanes, a new family of compounds generated by free radical catalysed action, independent of cyclooxygenase, are formed. 8-epi PGF 2a the most well known member exerts a great variety of proatherogenic actions, among them vasoconstriction and platelet activation it also serves as a mitogen and stimulator of endothelin release. The influence of various eicosanoids on lipoprotein modification, however, has not been assessed yet.
Export Options
About this article
Cite this article as:
Sobal Grazyna and Sinzinger H., Prostaglandins and Lipid Modification, Current Pharmaceutical Design 2001; 7 (6) . https://dx.doi.org/10.2174/1381612013397933
DOI https://dx.doi.org/10.2174/1381612013397933 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamics of Radical Intermediates in Prostaglandin H Synthase-1 Cyclooxygenase Reactions is Modulated by Multiple Factors
Protein & Peptide Letters Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Development and Characterization of a Clobetasol Propionate Nanostructured Lipid Carrier-Based Gel for the Treatment of Plaque Psoriasis
Current Molecular Pharmacology Systemic Inflammatory Response, Bacterial Translocation and Nitric Oxide Donors
Inflammation & Allergy - Drug Targets (Discontinued) Guinea Pig Model of Infectious Disease - Viral Infections
Current Drug Targets Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science subject Index To Volume 1
Current Molecular Medicine RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Epithelial Cell-Derived Antibacterial Peptides Human β-Defensins and Cathelicidin: Multifunctional Activities on Mast Cells
Current Drug Targets - Inflammation & Allergy Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Chlamydial Heat Shock Protein 60 and Lipopolysaccharide: Potential Virulence Determinants in Atherogenesis
Current Drug Targets - Inflammation & Allergy The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Prenatal Pregabalin Exposure Alters Postnatal Pain Sensitivity and Some Behavioral Responses in Adult Offspring Rats
Current Drug Safety The Concept of Protein Mosaics: Physiological Role and Relevance for Prion Disease
Current Proteomics